Affiliation:
1. The First Affiliated Hospital of Chongqing Medical University
2. Yubei District people's Hospital of Chongqing
Abstract
Abstract
Background.The purpose of this study was to explore the short-term efficacy and safety of neoadjuvant chemotherapy combined with arterial chemoembolization for locally advanced gastric cancer (LAGC).
Methods. We retrospectively analyzed the clinical data of 203 patients with LAGC who received neoadjuvant therapy from June 2019 to December 2021. The patients were divided into neoadjuvant chemotherapy combined with arterial chemoembolization group (Combined group, n=102) and neoadjuvant chemotherapy group (Conventional group, n=101). The adverse events of chemotherapy, postoperative complications and pathological complete response (pCR) rate were compared between the two groups. The potential factors of influencing pCR were evaluated by univariate analysis and multivariate analysis. The univariate and multivariate analysis were performed to evaluate the potential factors affecting pCR.
Results. 78.8% of patients were in clinical stage III before neoadjuvant therapy. 52.2% patients underwent surgery after receiving two cycles of neoadjuvant therapy. There were 21.2% patients with≥ grade 3 (CTCAE 4.0) adverse events of chemotherapy and 11.3% patients with Clavien-Dindo classification ≥ grade 3 postoperative complications. Compared with the conventional group, the combination group did not increase the adverse events of chemotherapy and postoperative complications. The pCR rate in the combined group was significantly higher than that in the conventional group (16.7% vs 4.95%, P=0.012). Multivariate analysis showed that arterial chemoembolization, pre-treatment neutrophil-to-lymphocyte ratio (NLR) and pre-treatment platelet-to-lymphocyte ratio (PLR) were independent factors affecting pCR.
Conclusion.Neoadjuvant chemotherapy combined with arterial chemoembolization contributed to improving the pCR rate of LAGC patients. Arterial chemoembolization, pre-treatment NLR and pre-treatment PLR were also predictors of pCR.
Publisher
Research Square Platform LLC
Reference60 articles.
1. Gastric cancer;Smyth EC;Lancet,2020
2. Gastric cancer: epidemiology, prevention, classification, and treatment;Sitarz R;Cancer Manag Res,2018
3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA Cancer J Clin,2021
4. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; S0923-7534(22)01851-8. doi: 10.1016/j.annonc.2022.07.004.
5. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology;Ajani JA;J Natl Compr Canc Netw,2022